Roles of microRNAs in Ovarian Cancer Tumorigenesis: Two Decades Later, What Have We Learned?

被引:62
|
作者
Alshamrani, Ali A. [1 ]
机构
[1] King Saud Univ, Dept Pharmacol & Toxicol, Coll Pharm, Riyadh, Saudi Arabia
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
microRNA; ovarian cancer; proliferation; biomarkers; chemoresistance; diagnosis; prognosis; target genes; GLUTATHIONE-S-TRANSFERASE; SUPPRESSES TUMOR-GROWTH; PROMOTES CELL-GROWTH; CISPLATIN RESISTANCE; DOWN-REGULATION; MIR-200; FAMILY; UP-REGULATION; ENHANCES CHEMOSENSITIVITY; MULTIDRUG-RESISTANCE; INHIBITS METASTASIS;
D O I
10.3389/fonc.2020.01084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is one of the top gynecological malignancies that cause deaths among females in the United States. At the molecular level, significant progress has been made in our understanding of ovarian cancer development and progression. MicroRNAs (miRNAs) are short, single-stranded, highly conserved non-coding RNA molecules (19-25 nucleotides) that negatively regulate target genes post-transcriptionally. Over the last two decades, mounting evidence has demonstrated the aberrant expression of miRNAs in different human malignancies, including ovarian carcinomas. Deregulated miRNAs can have profound impacts on various cancer hallmarks by repressing tumor suppressor genes. This review will discuss up-to-date knowledge of how the aberrant expression of miRNAs and their targeted genes drives ovarian cancer initiation, proliferation, survival, and resistance to chemotherapies. Understanding the mechanisms by which these miRNAs affect these hallmarks should allow the development of novel therapeutic strategies to treat these lethal malignancies.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Fibromyalgia syndrome a decade later -: What have we learned?
    Goldenberg, DL
    ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (08) : 777 - 785
  • [22] A decade later, what have we learned about Brazil?
    Gomes, Geovane Ferreira
    Pacifico, Marsiel
    REVISTA HISTORIA-DEBATES E TENDENCIAS, 2024, 24 (03): : 205 - 221
  • [23] Two decades since the fetal insulin hypothesis: what have we learned from genetics?
    Hughes, Alice E.
    Hattersley, Andrew T.
    Flanagan, Sarah E.
    Freathy, Rachel M.
    DIABETOLOGIA, 2021, 64 (04) : 717 - 726
  • [24] Emergency response for Phytophthora ramorum: What have we learned over the past two decades?
    Frankel, S. J.
    PHYTOPATHOLOGY, 2021, 111 (10) : 183 - 183
  • [25] Two decades since the fetal insulin hypothesis: what have we learned from genetics?
    Alice E. Hughes
    Andrew T. Hattersley
    Sarah E. Flanagan
    Rachel M. Freathy
    Diabetologia, 2021, 64 : 717 - 726
  • [26] Five decades of Fontan palliation: What have we learned? What should we expect?
    Hassan, Adil
    Chegondi, Madhuradhar
    Porayette, Prashob
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2023, 51 (10)
  • [27] Lung Cancer Screening with Low-Dose CT: What We Have Learned in Two Decades of ITALUNG and What Is Yet to Be Addressed
    Mascalchi, Mario
    Picozzi, Giulia
    Puliti, Donella
    Diciotti, Stefano
    Deliperi, Annalisa
    Romei, Chiara
    Falaschi, Fabio
    Pistelli, Francesco
    Grazzini, Michela
    Vannucchi, Letizia
    Bisanzi, Simonetta
    Zappa, Marco
    Gorini, Giuseppe
    Carozzi, Francesca Maria
    Carrozzi, Laura
    Paci, Eugenio
    DIAGNOSTICS, 2023, 13 (13)
  • [28] Liver cancer mortality over six decades in an epidemic area: what we have learned
    Chen, Jian-Guo
    Zhu, Jian
    Zhang, Yong-Hui
    Chen, Yong-Sheng
    Lu, Jian-Hua
    Zhu, Yuan-Rong
    Chen, Hai-Zhen
    Shen, Ai-Guo
    Wang, Gao-Ren
    Groopman, John D.
    Kensler, Thomas W.
    PEERJ, 2021, 9
  • [29] Three decades of environmental planning: what have we really learned?
    Selman, P
    PLANNING SUSTAINABILITY, 1999, : 148 - 174
  • [30] RESTRUCTURING SCHOOLS FOR EQUITY - WHAT WE HAVE LEARNED IN 2 DECADES
    BANKS, CAM
    PHI DELTA KAPPAN, 1993, 75 (01) : 42 - &